Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lusher

Showing results (161-170 of 177) with videos related to

Pageof 18
Sort By:
Thrombosis and Haemostasis|September 1, 1995
Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTHC K Kasper, D L Aronson, G Davignon, et al.
Vox Sanguinis|January 1, 1990
Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study GroupS L Dietrich, J W Mosley, J M Lusher, et al.
Pediatrics|August 1, 1991
Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disordersJ M Lusher, E A Operskalski, L M Aledort, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Factor IX inhibitors and anaphylaxis in haemophilia BI Warrier, B M Ewenstein, M A Koerper, et al.
British Journal of Haematology|September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study GroupsD Menache, D L Aronson, F Darr, et al.
Blood|May 24, 2003
Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusionJerry S Powell, Margaret V Ragni, Gilbert C White, et al.
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
Blood|February 15, 1997
Acute idiopathic thrombocytopenic purpura--management in childhoodG R Buchanan, P A de Alarcon, S A Feig, et al.
Journal of Pediatric Hematology/Oncology|January 1, 1997
Factor IX inhibitors and anaphylaxis in hemophilia BI Warrier, B M Ewenstein, M A Koerper, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Factor IX inhibitors and anaphylaxis in hemophilia BI Warrier, B M Ewenstein, M A Koerper, et al.
Pageof 18

Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Thrombosis and Haemostasis|September 1, 1995
Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTHC K Kasper, D L Aronson, G Davignon, et al.
Vox Sanguinis|January 1, 1990
Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study GroupS L Dietrich, J W Mosley, J M Lusher, et al.
Pediatrics|August 1, 1991
Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disordersJ M Lusher, E A Operskalski, L M Aledort, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Factor IX inhibitors and anaphylaxis in haemophilia BI Warrier, B M Ewenstein, M A Koerper, et al.
British Journal of Haematology|September 1, 1996
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study GroupsD Menache, D L Aronson, F Darr, et al.
Blood|May 24, 2003
Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusionJerry S Powell, Margaret V Ragni, Gilbert C White, et al.
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
Blood|February 15, 1997
Acute idiopathic thrombocytopenic purpura--management in childhoodG R Buchanan, P A de Alarcon, S A Feig, et al.
Journal of Pediatric Hematology/Oncology|January 1, 1997
Factor IX inhibitors and anaphylaxis in hemophilia BI Warrier, B M Ewenstein, M A Koerper, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 24, 2016
Factor IX inhibitors and anaphylaxis in hemophilia BI Warrier, B M Ewenstein, M A Koerper, et al.
Pageof 18